Blood cancer Clinical Trials in Chapel Hill, NC
As of July 2026, 48 paid clinical trials are recruiting for Blood cancer in Chapel Hill, North Carolina. Blood cancer trials investigate CAR-T cell therapies, bispecific antibodies, BTK and BCL-2 inhibitors, and novel combinations across leukemias, lymphomas, myeloma, and myelodysplastic syndromes. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Chapel Hill
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
49 clinical trials for Blood cancer
·Clear filters·↓ Download CSVA Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
A Study of Revumenib and Mezigdomide in People With Leukemia
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Project: Every Child for Younger Patients With Cancer
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Implementation of an Oral Chemotherapy Adherence Intervention
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Registry of Older Patients With Cancer
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
About research studies in Chapel Hill
Chapel Hill has approximately 696 recruiting research studies across a wide range of therapeutic areas. North Carolina hosts Duke University Medical Center, UNC Health, and Wake Forest Baptist Health, with strong programs in oncology, cardiovascular disease, and translational research anchored by Research Triangle Park.
Top Research Study Locations in Chapel Hill
Researchers run research studies in Chapel Hill, NC at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| University of North Carolina at Chapel Hill | ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome | 146 |
| University of North Carolina | Breast Cancer, Metastatic Breast Cancer, Ulcerative Colitis | 98 |
| UNC Lineberger Comprehensive Cancer Center | Acute Myeloid Leukemia, Anatomic Stage II Breast Cancer AJCC v8, Breast Cancer | 87 |
| The University of North Carolina at Chapel Hill | Hypertension, ACL Tear, Aortic Stenosis | 18 |
| UNC Chapel Hill | Lupus Nephritis, Lymphatic Malformations, Barrett's Esophagus | 17 |
| University of North Carolina Chapel Hill | Alport Syndrome, Articular Fractures, Asthma (Diagnosis) | 13 |
| Lineberger Comprehensive Cancer Center | Endometrial Cancer, Adolescent and Young Adult With Brain Cancer, Advanced Solid Tumors | 12 |
| University of North Carolina Medical Center | Breast Neoplasms, Neoplasm Metastasis, Atrial Fibrillation | 10 |
| University of North Carolina - Chapel Hill | Obstetrical Complications, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | 9 |
| University of North Carolina, Chapel Hill | Hearing Loss, Sensorineural, Acute Myeloid Leukemia (AML), Aging | 9 |
| UNC Hospitals, The University of North Carolina at Chapel Hill | Cachexia, Melanoma, Cutaneous Malignant, Metastatic Melanoma | 9 |
| Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill | Breast Cancer, Chronic Myeloproliferative Disorders, Leukemia | 8 |
| UNC Hospitals | Comparative Effectiveness, Family Engagement, Health Care | 8 |
| University of North Carolina at Chapel Hill, Department of Radiation Oncology | Head and Neck Cancer, Sarcoma, Cancer | 6 |
| Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill | Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II | 5 |
| University of North Carolina At Chapel Hill | Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasms, Small Lymphocytic Lymphoma | 5 |
| The University of North Carolina | Breast Cancer, Breast Neoplasms, Kidney Neoplasms | 4 |
| UNC Hospitals, University of North Carolina at Chapel Hill | Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement | 4 |
| UNC-Chapel Hill | Binge Eating, Binge-Eating Disorder, Obesity | 4 |
| Univeristy of North Carolina at Chapel Hill | Cystic Fibrosis, Drug Induced Liver Injury, Endometrial Cancer | 4 |
| University of North Carolina School of Medicine | Barrett Esophagus, Barretts Esophagus With Dysplasia, Brain Injury | 4 |
| Clinical Trial Site | AQP4+ NMOSD, Generalized Myasthenia Gravis, Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | 3 |
| North Carolina Children's Hospital: Department of Pediatrics, Division of Allergy, Immunology and Rheumatology | Allergy, Alpha-Gal Syndrome, Peanut Allergy | 3 |
| UNC | Acute Kidney Injury, Chronic Kidney Disease(CKD), Epidemiology | 3 |
| UNC Center for Health Promotion and Disease Prevention | Child Obesity, Down Syndrome, Obesity | 3 |
Active & Upcoming Studies in Chapel Hill (2026)
Recruiting trials in Chapel Hill grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (239 active studies)
- Improving Affordability in Cancer Care Through Economic Screening and Support (I-ACCESS) · UNC Lineberger Comprehensive Cancer Center
- Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer · Phase 2 · UNC Lineberger Comprehensive Cancer Center
Diabetes & metabolic (43 active studies)
- Optimization of Dietary Adherence in a Mobile Weight Loss Intervention · UNC Lineberger Comprehensive Cancer Center
- A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide · Phase 3 · Novo Nordisk A/S
Cardiovascular (27 active studies)
- A Study of LY3971297 in Participants With Heart Failure · Phase 1 · Eli Lilly and Company
- Personalized Care for Prenatal Stress Reduction & Prevention of Preterm Birth (PTB) Disparities · University of North Carolina, Chapel Hill
Neurology & pain (20 active studies)
- Early Dental Risk Screening for Pediatric Sleep-Disordered Breathing · University of North Carolina, Chapel Hill
- Neural Mechanisms of Light Driven Analgesia · University of North Carolina, Chapel Hill
Pediatric (18 active studies)
- The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma · Phase 2 · Wake Forest University Health Sciences
- Adolescent Mental Health Parenting Program for Child-Adult Relationship Enhancement · University of North Carolina, Chapel Hill
HIV / STI (13 active studies)
- A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
- Small Trial of Alendronate Impact on the Reservoir of HIV · Phase 2 · National Institute of Allergy and Infectious Diseases (NIAID)
Mental health & behavior (12 active studies)
- Testing STAR and TextSTAR: A Randomized Controlled Trial · University of Wisconsin, Madison
- Teen Vulnerability to Irritability: Brain and Estrogen Changes · Phase 4 · University of North Carolina, Chapel Hill
Vaccines (3 active studies)
- Woodsmoke Exposure, Influenza Infection, and Nasal Immunity · Phase 4 · University of North Carolina, Chapel Hill
- Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children · Phase 3 · University of Alabama at Birmingham
Eye & vision (1 active study)
- Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial · University of Pennsylvania
Common conditions studied in Chapel Hill
- Breast Cancer (28 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Cancer (15 active studies). Recruiting Cancer studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Multiple Myeloma (15 active studies). Recruiting Multiple Myeloma studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Obesity (12 active studies). Obesity trials evaluate GLP-1 and GIP receptor agonists, novel metabolic drugs, and combined lifestyle interventions for sustainable weight loss.
- Ulcerative Colitis (10 active studies). Ulcerative colitis trials examine biologic therapies, S1P receptor modulators, and oral small molecules for steroid-sparing remission.
- Acute Myeloid Leukemia (9 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
Leading research sponsors in Chapel Hill
- University of North Carolina, Chapel Hill
- UNC Lineberger Comprehensive Cancer Center
- National Cancer Institute (NCI)
- Children's Oncology Group
- AbbVie
Local regulations and guidelines
Clinical trials in North Carolina are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. North Carolina research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Chapel Hill. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Chapel Hill
Hipa.ai aggregates every recruiting study in Chapel Hill from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Chapel Hill?
There are approximately 696 recruiting clinical trials in Chapel Hill, North Carolina listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Chapel Hill pay participants?
Most recruiting trials in Chapel Hill compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Chapel Hill?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Chapel Hill?
The most common conditions under active study in Chapel Hill include Breast Cancer (28), Cancer (15), Multiple Myeloma (15), Obesity (12), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Chapel Hill?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Chapel Hill on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Chapel Hill?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Chapel Hill?
Recruiting research sites in Chapel Hill include University of North Carolina at Chapel Hill, University of North Carolina, UNC Lineberger Comprehensive Cancer Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Chapel Hill right now?
The largest active categories in Chapel Hill are Cancer & tumors (239), Diabetes & metabolic (43), Cardiovascular (27). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.